Grufity logo
Grufity logo
PRPH

PRPH - ProPhase Labs Inc Stock Price, Fair Value and News

$0.020.00 (0.00%)
Market Closed as of 11 Sep 2026, 04:00 pm ET

PRPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRPH Price Action

Last 30 days

-50%

Last 90 days

-75%

Trailing 12 Months

-99.6%

PRPH RSI Chart

PRPH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PRPH Valuation

Market Cap

280.3K

Price/Earnings (Trailing)

-0.01

Price/Sales (Trailing)

0.07

EV/EBITDA

-0.03

Price/Free Cashflow

-0.06

PRPH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PRPH Fundamentals

PRPH Revenue

Revenue (TTM)

4.3M

Rev. Growth (Yr)

-18.93%

Rev. Growth (Qtr)

-13.52%

PRPH Earnings

Earnings (TTM)

-19.5M

Earnings Growth (Yr)

31.78%

Earnings Growth (Qtr)

41.04%

PRPH Profitability

EBT Margin

-406.71%

Return on Equity

628%

Return on Assets

-34.03%

Free Cashflow Yield

-1.6K%

PRPH Investor Care

Dividend Yield

15.0K%

Dividend/Share (TTM)

3

Shares Dilution (1Y)

237.40%

Diluted EPS (TTM)

-3.34

Revenue & Growth

How ProPhase Labs Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20264.7M4.3M--
20255.8M5.6M5.1M-
202427.9M20.9M13.8M6.8M
202394.4M78.5M62.7M35.0M
2022111.3M131.3M146.0M122.6M
202127.9M33.4M39.0M79.0M
20209.4M11.4M12.5M14.5M
201912.0M10.5M10.8M9.9M
201812.5M13.8M13.2M13.1M
20174.0M4.8M6.5M9.9M
201615.8M14.6M11.6M4.2M
201521.8M22.2M21.4M20.6M
201423.7M23.5M22.7M22.1M
201323.9M24.0M24.5M25.0M
201220.3M20.5M20.8M22.4M
2011-16.3M16.2M17.5M
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About ProPhase Labs Inc

PRPH
ProPhase Labs, Inc. engages in the development and commercialization of novel drugs, dietary supplements, and compounds in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It provides a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. The company also offers contract manufacturing services, such as consumer product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, it is involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
 CEO
 WEBSITEprophaselabs.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES129

ProPhase Labs Inc Frequently Asked Questions

PRPH is the stock ticker symbol of ProPhase Labs Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Sep 11 2026, market cap of ProPhase Labs Inc is 280.32 Thousand. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Sep 11 2026, PRPH's PE ratio (Price to Earnings) is -0.01 and Price to Sales (PS) ratio is 0.07. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRPH PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, ProPhase Labs Inc has provided -0.497 (multiply by 100 for percentage) rate of return.